Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.
about
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusEmpagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Tofogliflozin: first global approval.The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 DiabetesNovel Agents for the Treatment of Type 2 Diabetes.Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight.Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapySodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.Novel effective drugs for diabetic kidney disease? or not?Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phaDifferential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin.Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus.Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humansPreclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.
P2860
Q26750510-ED6D889A-3938-4EA8-AFF9-4EE77956F9B7Q26782225-7BEE4ACD-266D-4309-8AF9-C0D46103BB6CQ33837017-64F7C178-2295-4AC8-93E0-069A829682BCQ34420901-5FC8347A-5946-4EE6-BF15-C617AD719931Q35903101-20E520B2-360E-4488-91F4-266922A5A233Q35910421-CD8CEA5B-5817-4ED6-BB06-1468C3AB19BBQ36131466-9D6602A9-BE18-4360-9B3E-58A6D47919ACQ36357997-63284455-C0AE-41C6-A20F-88080CD086C6Q37219076-012FB321-7B17-4081-8B61-888C2D8C0EF2Q37461695-23ADA1D9-A0E3-40EE-8C66-B91EA3479C76Q37722896-AF22BA50-20A0-4F9C-B9FC-A068EF34D9ECQ38175467-5D8A062B-431B-41F4-8760-A7D7D0E2211BQ38265818-299CB5BC-627D-4112-98B7-03D72EF46B74Q38524435-62D88098-475D-43DA-A26F-F3C6787E7876Q38936746-862A0B61-86AB-4675-B886-A7D2E4CBC8E6Q39000172-85AF78F4-EA9C-45C3-8338-EA9174B6213AQ39017610-0105DC75-48A6-44FD-AFA1-BECAE60E17EBQ39170860-D44D425A-C427-4D3E-9754-C1C95140EF1DQ39296548-38AA9DB9-E74F-42EC-9441-CF9C4CC9D1C4Q39300057-3D27A823-9452-429A-868E-B746F6C9437BQ39300071-82DA2BA3-3CB7-46F0-9417-73C32797F272Q41649918-DBA3CDB6-4BA9-45C3-A4B4-8A628D0B23E5Q46650678-3719FD51-453B-4998-8649-F96E3E2F4817Q46986653-60E231BF-1B0B-498A-AC6B-8DE53F8BD482
P2860
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Differentiating sodium-glucose ...... t of type 2 diabetes mellitus.
@en
type
label
Differentiating sodium-glucose ...... t of type 2 diabetes mellitus.
@en
prefLabel
Differentiating sodium-glucose ...... t of type 2 diabetes mellitus.
@en
P2860
P1476
Differentiating sodium-glucose ...... t of type 2 diabetes mellitus.
@en
P2093
Simon M Poucher
William N Washburn
P2860
P304
P356
10.1517/13543784.2013.774372
P407
P577
2013-03-01T00:00:00Z